XKRX
298380
Market cap1.92bUSD
Apr 11, Last price
56,200.00KRW
1D
-1.06%
1Q
81.00%
IPO
204.61%
Name
ABL Bio Inc
Chart & Performance
P/E
—
P/S
41.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
65.55b
Net income
-2.65b
CFO
-28.36b
Earnings
May 12, 2025
Profile
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY |
|---|---|
| 2023‑12 | |
| Income | |
Revenues | 65,547,055 |
Cost of revenue | 60,025,011 |
Unusual Expense (Income) | |
NOPBT | 5,522,044 |
NOPBT Margin | 8.42% |
Operating Taxes | |
Tax Rate | |
NOPAT | 5,522,044 |
Net income | (2,646,663) |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | 1,716,982 |
BB yield | |
| Debt | |
Debt current | (31,129,924) |
Long-term debt | 44,091,523 |
Deferred revenue | |
Other long-term liabilities | 1,151,847 |
Net debt | (60,946,805) |
| Cash flow | |
Cash from operating activities | (28,361,975) |
CAPEX | (5,739,981) |
Cash from investing activities | 29,883,582 |
Cash from financing activities | 1,436,848 |
FCF | |
| Balance | |
Cash | 71,165,345 |
Long term investments | 2,743,059 |
Excess cash | 70,631,051 |
Stockholders' equity | (289,680,536) |
Invested Capital | 408,849,491 |
ROIC | 1.35% |
ROCE | 4.63% |
| EV | |
Common stock shares outstanding | 47,844 |
Price | |
Market cap | |
EV | |
EBITDA | 8,111,822 |
EV/EBITDA | |
Interest | 2,150,649 |
Interest/NOPBT | 38.95% |